Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
TENAX THERAPEUTICS, INC. (symbol ING) is reported to have a significant shareholder position held through ING Groep N.V. and its wholly owned subsidiary ING Capital Markets LLC. These reporting persons disclose beneficial ownership of 2,639,666 shares of Tenax common stock, with shared voting and dispositive power over all of these shares and no sole power.
This position represents approximately 7.05% of Tenax’s common stock, based on 37,423,917 shares outstanding as of July 28, 2026, as referenced from Tenax’s Form 10‑Q for the quarter ended June 30, 2026. The filing is made on a Schedule 13G, indicating a passive beneficial ownership disclosure rather than an activist intent.
Key Figures
Shares beneficially owned:2,639,666 shares of Common StockPercent of class:7.05%Shares outstanding:37,423,917 shares of Common Stock+3 more
6 metrics
Shares beneficially owned2,639,666 shares of Common StockBeneficially owned by each of ING Groep N.V. and ING Capital Markets LLC
Percent of class7.05%Beneficial ownership of Tenax Therapeutics common stock as of July 28, 2026
Shares outstanding37,423,917 shares of Common StockTenax Therapeutics shares outstanding as of July 28, 2026 per Form 10‑Q
Shared voting power2,639,666 sharesShares over which the reporting persons have shared power to vote or direct the vote
Shared dispositive power2,639,666 sharesShares over which the reporting persons have shared power to dispose or direct disposition
Par value per share$0.0001 per sharePar value of Tenax Therapeutics common stock
Key Terms
beneficial owner, shared voting power, shared dispositive power, Common Stock, $0.0001 par value per share, +1 more
5 terms
beneficial ownerfinancial
"ING Groep N.V. may be deemed to be the <b>beneficial owner</b> of 2,639,666 Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting powerfinancial
"6 | <b>Shared Voting Power</b> 2,639,666.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Common Stock, $0.0001 par value per sharefinancial
"Title of class of securities: <b>Common Stock, $0.0001 par value per share</b>"
Schedule 13Gregulatory
"form_type": "<b>SCHEDULE 13G</b>""
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Tenax Therapeutics, Inc. (ING) does ING Groep N.V. report owning?
ING Groep N.V. and ING Capital Markets LLC report beneficial ownership of approximately 7.05% of Tenax Therapeutics’ common stock, based on 37,423,917 shares outstanding as of July 28, 2026, as referenced from Tenax’s Form 10‑Q for the quarter ended June 30, 2026.
How many Tenax Therapeutics, Inc. (ING) shares are reported as beneficially owned?
ING Groep N.V. and ING Capital Markets LLC report beneficial ownership of 2,639,666 shares of Tenax Therapeutics, Inc. common stock, with shared voting and dispositive power over all of these shares and no sole power to vote or dispose.
What is the total Tenax Therapeutics, Inc. (ING) share count used to calculate the 7.05% stake?
The reported ownership percentage is based on 37,423,917 shares of Tenax Therapeutics common stock outstanding as of July 28, 2026, as reported in the company’s Quarterly Report on Form 10‑Q for the period ended June 30, 2026.
Do ING Groep N.V. and ING Capital Markets LLC have sole or shared voting power over Tenax (ING) shares?
They report 0 shares with sole voting power and 2,639,666 shares with shared voting power. They also report 0 shares with sole dispositive power and 2,639,666 shares with shared dispositive power over Tenax Therapeutics common stock.
Who are the reporting persons in this Schedule 13G related to Tenax Therapeutics, Inc. (ING)?
The reporting persons are ING Groep N.V., organized in the Netherlands, and its wholly owned subsidiary ING Capital Markets LLC, organized in Delaware. Both may be deemed beneficial owners of the same 2,639,666 shares of Tenax Therapeutics common stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Tenax Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
88032L605
(CUSIP Number)
08/19/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
88032L605
1
Names of Reporting Persons
ING Groep N.V.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,639,666.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,639,666.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,639,666.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.05 %
12
Type of Reporting Person (See Instructions)
HC
Comment for Type of Reporting Person: * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.
SCHEDULE 13G
CUSIP Number(s):
88032L605
1
Names of Reporting Persons
ING Capital Markets LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,639,666.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,639,666.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,639,666.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.05 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Tenax Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517, USA
Item 2.
(a)
Name of person filing:
ING Groep, N.V.
ING Capital Markets LLC
(b)
Address or principal business office or, if none, residence:
ING Groep N.V.
PO Box 1800
Amsterdam, P7
1000 BV Amsterdam
ING Capital Markets LLC
1133 Avenue of the Americas
New York, NY 10036
USA
(c)
Citizenship:
ING Groep N.V. - The Netherlands
ING Capital Markets LLC - Delaware
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
88032L605
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
ING Groep N.V. may be deemed to be the beneficial owner of 2,639,666 Common Stock, held by ING Capital Markets LLC, a wholly owned subsidiary of ING Groep N.V. ING Capital Markets LLC may be deemed to be the beneficial owner of 2,639,666 Common Stock.
(b)
Percent of class:
Each of ING Groep N.V. and ING Capital Markets LLC may be deemed to be the beneficial owner of approximately 7.05% of Common Stock issued and outstanding as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
2639666
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
2639666
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
